Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11159668 | 1.00 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL3279736 | 0.96 | MGLL (0.48) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL8052312 | 0.96 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL5348508 | 0.96 | MGLL (0.51) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10958018 | 0.95 | MGLL (0.53) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10658773 | 0.95 | MGLL (0.53) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10658764 | 0.95 | MGLL (0.53) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10614061 | 0.94 | F2 (0.48) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL13367304 | 0.93 | MGLL (0.46) | MGLLPOLBHTTKMT2ASMN1; SMN2 | |
| SCHEMBL12736588 | 0.93 | MGLL (0.46) | MGLLPOLBKMT2ASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4389329-A | Meterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 1983-06-21 | — | — | US | claimed |
| EP-0014885-B1 | CYCLOHEXYLPYRIMIDINES, THEIR PREPARATION AND USE, AS WELL AS LIQUID CRYSTALS MIXTURES AND ELECTRO-OPTICAL APPARATUSES CONTAINING THESE COMPOUNDS AND THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-06-15 | — | — | EP | claimed |
| US-4364838-A | Liquid crystal mixtures | HOFFMANN-LA ROCHE INC. (US) | 1982-12-21 | — | — | US | claimed |
| US-4358393-A | MODULATORS FOR ELECTROOPTICAL APPARATUS; DISPLAYING; HIGH TEMPERATURE | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-11-09 | — | — | US | claimed |
| US-4348298-A | WITH DICHROIC DYESTUFF | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-09-07 | — | — | US | claimed |
| US-4323472-A | ELECTROOPTICAL DISPLAY | TIMEX CORPORATION (US) | 1982-04-06 | — | — | US | claimed |
| US-7923078-B2 | Light-modulating liquid-crystal element | ADEKA CORPORATION (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090279043-A1 | LIGHT-MODULATING LIQUID-CRYSTAL ELEMENT | ADEKA CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| US-4391731-A | Hydrogenated naphthalenes | HOFFMANN-LA ROCHE INC. (US) | 1983-07-05 | — | — | US | disclosed |
| US-4389329-A | Meterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 1983-06-21 | — | — | US | disclosed |
| US-4364838-A | Liquid crystal mixtures | HOFFMANN-LA ROCHE INC. (US) | 1982-12-21 | — | — | US | disclosed |
| US-4358589-A | TETRAZINES | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-11-09 | — | — | US | disclosed |
| US-4358393-A | MODULATORS FOR ELECTROOPTICAL APPARATUS; DISPLAYING; HIGH TEMPERATURE | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-11-09 | — | — | US | disclosed |
| US-4348298-A | WITH DICHROIC DYESTUFF | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-09-07 | — | — | US | disclosed |
| US-4273929-A | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | MGLL 2307/4885POLB 831/4885HTT 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.